• PUK20 PROFILING COMMON CO-MORBIDITIES AND MEDICATIONS PRESCRIBED AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE

    May 1, 2009, 00:00

  • PIN25 AN ECONOMIC EVALUATION OF POSACONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS WITH REFRACTORY DISEASE IN KOREA

    May 1, 2009, 00:00

  • PMC79 TRANSLATION OF THE PATIENT-REPORTED OUTCOMES MEASUREMENT INFORMATION SYSTEM INTO SPANISH

    May 1, 2009, 00:00

  • PHP39 THE EFFECT OF THE WITHDRAWAL OF VISIT FEE ON THE NUMBER OF PATIENT-VISITS TO OUTPATIENT CARE DEPARTMENTS IN HUNGARY

    May 1, 2009, 00:00

  • PMS54 THE EFFECTS OF THE PART D DOUGHNUT HOLE ON MEDICARE PATIENTS WHO REQUIRE HIGH-COST MEDICATIONS

    May 1, 2009, 00:00

  • PDB32 CHANGES IN OPIOID USE AND ECONOMIC OUTCOMES AMONG DIABETIC PERIPHERAL NEUROPATHIC PAIN PATIENTS TREATED WITH DULOXETINE

    May 1, 2009, 00:00

  • PMH4 PREVALENCE OF DEPRESSION IN EUROPE- A COMPARISON OF FIVE COUNTRIES

    May 1, 2009, 00:00

  • PGI16 FACTORS INFLUENCING GASTROESOPHAGEAL REFLUX DISEASE OUTPATIENTS CHOICES TO ACCESS DIFFERENT TIERS OF MEDICAL FACILITIES- THE PRELIMINARY STUDY OF A DISCRETE CHOICE EXPERIMENT

    May 1, 2009, 00:00

  • PSY12 TREATMENT OF TRANSFUSIONAL IRON OVERLOAD IN PATIENTS WITH MYELODYSPLASTIC SYNDROME OR SEVERE ANEMIA- DATA FROM MULTI-CENTER CLINICAL PRACTICES

    May 1, 2009, 00:00

  • PDB57 MEDICATION NONADHERENCE AND POTENTIALLY AVOIDABLE HOSPITALIZATIONS AMONG PATIENTS WITH DIABETES

    May 1, 2009, 00:00

  • PRS8 COSTS OF SMOKING IN SLOVAKIA FROM A PAYER PERSPECTIVE

    May 1, 2009, 00:00

  • PMH74 COMORBID ANXIETY AND HEALTH CARE UTILIZATION AMONG ADULTS WITH DEPRESSION

    May 1, 2009, 00:00

  • PCV20 ESTIMATE THE 10-YEAR CARDIOVASCULAR RISK IN THE GENERAL PUBLIC OF HONG KONG

    May 1, 2009, 00:00

  • PCV99 A LONGITUDINAL ANALYSIS OF ANGIOTENSIN RECEPTOR BLOCKER (ARB) PRESCRIBING PATTERNS UNDER A PRIOR-AUTHORIZATION REQUIREMENT

    May 1, 2009, 00:00

  • PIH13 COST-EFFECTIVENESS OF A SCHOOL-BASED TOBACCO-USE PREVENTION PROGRAM IN SPAIN

    May 1, 2009, 00:00

  • PUK21 IMPACTS OF THE PREVENTIVE TREATMENT OF PATIENTS SUFFERING FROM RECURRING CYSTITIS BY MEANS OF A STANDARD DRY CRANBERRY EXTRACT

    May 1, 2009, 00:00

  • PMH14 BUDGETARY IMPACT OF WELL DIRECTED USE OF PALIPERIDONE ER IN GERMANY

    May 1, 2009, 00:00

  • PMS39 IMPAIRMENTS IN QUALITY OF LIFE, DAILY FUNCTION, AND WORK PRODUCTIVITY AND ACTIVITY IN RHEUMATOID ARTHRITIS PATIENTS WHO USE SUBCUTANEOUS BIOLOGIC THERAPIES

    May 1, 2009, 00:00

  • PMS38 PATIENTS SUCCESS CRITERIA AND EXPECTATIONS IN FALLS REHABILITATION

    May 1, 2009, 00:00

  • PCN92 HOW DOES TRUST IN PHYSICIANS AFFECT PARENTS TREATMENT DECISION MAKING FOR THEIR CHILDREN WITH LIFE-LIMITING CONDITIONS?

    May 1, 2009, 00:00

  • PCV1 EVALUATING CLINICAL OUTCOMES OF AN EMPLOYER SPONSERED MULTI CENTER DIABETES AND HYPERTENSION MEDICATION THERAPY MANAGEMENT PROGRAM (MTMP)

    May 1, 2009, 00:00

  • MD6 PREDICTORS OF UTILIZATION OF ACE INHIBITORS AND ANGIOTENSIN II RECEPTOR BLOCKERS AMONG MEDICARE PART D ENROLLEES WITH DIABETES

    May 1, 2009, 00:00

  • PCN78 PREFERENCES IN MULTIPLE MYELOMA TREATMENT-WHAT DO PHYSICIANS THINK?

    May 1, 2009, 00:00

  • PMC47 USE OF STABILIZED INVERSE PROPENSITY SCORES AS WEIGHTS TO DIRECTLY ESTIMATE RELATIVE RISK AND ITS CONFIDENCE INTERVALS

    May 1, 2009, 00:00

  • PMH28 DIRECT COSTS OF PATIENTS WITH TREATMENT RESISTANT AND NON-TREATMENT RESISTANT MAJOR DEPRESSIVE DISORDER

    May 1, 2009, 00:00

  • PHP40 EVALUATING COST/EQUITY IN THE COLOMBIAN HEALTH SYSTEM, 1998-2005

    May 1, 2009, 00:00

  • PIH8 COMPARISON OF LEVONORGESTREL INTRAUTERINE SYSTEM (LNG-IUS) TO ORAL CONTRACEPTIVES (OC) ON CONTRACEPTION- A COST-EFFECTIVENESS ANALYSIS

    May 1, 2009, 00:00

  • PHP19 MEDICATION COSTS AND UTILIZATION IN A HOSPICE CARE

    May 1, 2009, 00:00

  • PIH43 HOURLY AND ANNUAL OBJECTIVE PRODUCTIVITY (PRESENTEEISM) ACROSS SEVERAL DISEASES- BIPOLAR DISORDER, OTHER MENTAL DISORDERS, CHRONIC CONSTIPATION, FUNCTIONAL DYSPEPSIA, GERD, GOUT, AND INSOMNIA

    May 1, 2009, 00:00

  • PCN69 COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER- A UK PERSPECTIVE

    May 1, 2009, 00:00

  • PCV107 SPECIFICITY OF ADMINISTRATIVE DATA FOR IDENTIFYING HEART FAILURE PATIENTS FOR HOSPITAL QUALITY PERFORMANCE INITIATIVES

    May 1, 2009, 00:00

  • PGI11 ECONOMIC EVALUATION OF INFLIXIMAB AND ADALIMUMAB FOR CROHNS DISEASE

    May 1, 2009, 00:00

  • PSS23 PHYSICIANS AWARENESS, ATTITUDE, AND BEHAVIOR TO USE THE WAIT AND WATCH APPROACH FOR THE TREATMENT OF ACUTE OTITIS MEDIA

    May 1, 2009, 00:00

  • PCN51 PROJECTED LONG-TERM ECONOMIC OUTCOMES ASSOCIATED WITH BEVACIZUMAB TREATMENT IN PATIENTS WITH ADJUVANT TRIPLENEGATIVE BREAST CANCER TO INFORM EARLY DECISION MAKING

    May 1, 2009, 00:00

  • PIN3 ECONOMIC ANALYSIS OF MICAFUNGIN VERSUS CASPOFUNGIN THERAPY FOR THE TREATMENT OF CANDIDEMIA AND PNEUMONIA INFECTIONS

    May 1, 2009, 00:00

  • PSY34 IMPACT OF OBESITY ON HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH ASTHMA IN THE USA

    May 1, 2009, 00:00

  • PCN102 IMPACT OF RADIOTHERAPY SEQUENCE WITH SURGERY ON SURVIVAL FOR PATIENTS WITH RESECTABLE COLORECTAL CANCER

    May 1, 2009, 00:00

  • PHC2 SOCIOECONOMIC STATUS AND COST OF CARE IN THE ELDERLY UNDERGOING MAJOR ORTHOPEDIC SURGERY

    May 1, 2009, 00:00

  • PMH8 GROWTH AND DIFFUSION OF ANTIPSYCHOTIC MEDICINES FOR LABELED AND OFF-LABELED USES, 1994-2007

    May 1, 2009, 00:00

  • PIN15 COMPARING COST-EFFECTIVENESS OF THE THREE- VERSUS TWO-DOSE VACCINATION PROTOCOL AGAINST HEPATITIS B IN ADOLESCENTS

    May 1, 2009, 00:00

  • PMC91 REPORTING QUALITY OF DOUBLE-BLIND RANDOMIZED CONTROLLED TRIALS AND ITS ASSOCIATION WITH THE FUNDING AGENCY

    May 1, 2009, 00:00

  • PSY23 ECONOMIC EVALUATION OF DARBEPOETIN ALFA AND EPOETIN IN HEMODIALYSIS PATIENTS WITH ANEMIA AND CHRONIC KIDNEY DISEASE

    May 1, 2009, 00:00

  • PMC69 MULTITRAIT-MULTIMETHOD ANALYSIS OF THREE GENERIC PREFERENCE-BASED HEALTH-RELATED QUALITY OF LIFE MEASURES IN THE NATIONAL HEALTH MEASUREMENT STUDY

    May 1, 2009, 00:00

  • PHP37 REGIONAL VARIATION IN MEDICAID ENROLLMENT AMONG MEDICAL EXPENDITURE PANEL SURVEY (MEPS) POPULATION

    May 1, 2009, 00:00

  • PIH21 DRIVERS OF HEALTH CARE COSTS IN WOMEN WITH HYPOACTIVE SEXUAL DESIRE DISORDER (HSDD)

    May 1, 2009, 00:00

  • PIH6 DEVELOPING EVIDENCE-BASED TRADITIONAL CHINESE MEDICINE THROUGH OUTCOME RESEARCH

    May 1, 2009, 00:00

  • PIH12 COMPARISON OF YAZ TO SSRIS IN THE TREATMENT OF PREMENSTRUAL DYSPHRORIC DISORDER- COST-EFFECTIVENESS ANALYSIS

    May 1, 2009, 00:00

  • PMC71 APPLICATION AND FURTHER VALIDATION OF A PATIENT-REPORTED OUTCOME INSTRUMENT- PATIENT SATISFACTION WITH PHARMACEUTICAL CARE QUESTIONNAIRE

    May 1, 2009, 00:00

  • PCN26 COMPARISON OF EPOETIN ALFA AND DARBEPOETIN ALFA DOSING PATTERNS AND COSTS IN CANCER INPATIENTS RECEIVING CHEMOTHERAPY

    May 1, 2009, 00:00

  • PRS10 RETURN ON INVESTMENT FROM SMOKING CESSATION INSURANCE COVERAGE IN THE WORKPLACE- A CANADIAN EMPLOYERS PERSPECTIVE

    May 1, 2009, 00:00

  • PSY25 MEDICAL TREATMENT COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH ASTHMA AMONG U.S. ADULTS

    May 1, 2009, 00:00

  • PMH50 THE VALIDATION OF TURKISH VERSION OF PERSONAL AND SOCIAL PERFORMANCE SCALE (PSP)

    May 1, 2009, 00:00

  • PIN9 INCREASING THE AVAILABILITY OF ATAZANAVIR IN THE MINISTRY OF HEALTH (MOH) PUBLIC INSTITUTIONS IN MEXICO- A BUDGET IMPACT ANALYSIS

    May 1, 2009, 00:00

  • PMS14 THE RELATIONSHIP BETWEEN SURGICAL DELAY OVER 24 HOURS AND 30 DAYS MORTALITY FOLLOWING FEMORAL NECK FRACTURE IN THE PRESENCE OF DIFFERENT CO-MORBIDITIES

    May 1, 2009, 00:00

  • PCV76 RELATIONSHIP BETWEEN HEALTH LITERACY, OUTCOME EXPECTATIONS, EFFICACY EXPECTATIONS AND MEDICATION ADHERENCE

    May 1, 2009, 00:00

  • PDB2 A1C AND WEIGHT OUTCOMES FOLLOWING 6 MONTHS OF ANALOG BASAL INSULIN IN INSULIN NAVE PATIENTS WITH TYPE-2 DIABETES IN AN AMBULATORY CARE SETTING

    May 1, 2009, 00:00

  • PMC81 ELECTRONIC PATIENT REPORTED OUTCOMES- FOLLOWING FDA GUIDANCE FROM A VENDOR PERSPECTIVE

    May 1, 2009, 00:00

  • PSY37 THE OBESITY TRENDS IN GENERAL POPULATION OF THE REPUBLIC OF SERBIA

    May 1, 2009, 00:00

  • PCV104 ANALYSIS OF ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS IN THE US MEDICAID PROGRAM FROM 1991 TO 2007

    May 1, 2009, 00:00

  • PRS5 RELATIONSHIP BETWEEN EXACERBATIONS OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) AND DURATION OF CONTROLLER THERAPY AMONG A COMMERCIALLY INSURED POPULATION IN THE UNITED STATES

    May 1, 2009, 00:00

  • PMH49 ASSESSMENT OF TYPE 2 DIABETES MELLITUS PATIENTS WITH AND WITHOUT SYMPTOMS OF ADHD- PATIENT CHARACTERISTICS AND RESOURCE UTILIZATION DATA FROM AN INTERNET-BASED SURVEY

    May 1, 2009, 00:00

  • PRS38 CONTINUOUS TREATMENT WITH FIXED COMBINATION OF LABA/ICS CAN AVOID COSTS OF HOSPITALIZATION IN ASTHMA AND COPD IN GERMANY

    May 1, 2009, 00:00

  • PCN109 BREAST CANCER PREVALENCE AND HEALTH CARE UTILIZATION AND COST TRENDS AMONG FEE-FOR-SERVICE FEMALE RECIPIENTS IN A STATE MEDICAID PROGRAM

    May 1, 2009, 00:00

  • PIN51 HOSPITAL LENGTH OF STAY AND COSTS ASSOCIATED WITH INAPPROPRIATE TREATMENT OF CANDIDEMIA IN THE ICU

    May 1, 2009, 00:00

  • PUK15 QUALITY OF LIFE IN A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED STUDY OF OXYBUTYNIN CHLORIDE TOPICAL GEL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER

    May 1, 2009, 00:00

  • PND40 EXPLORING THE IMPACT OF DISPENSING CHANNEL ON MEDICATION ADHERENCE AMONG MULTIPLE SCLEROSIS PATIENTS

    May 1, 2009, 00:00

  • PCN57 ASSESSING THE MAJOR DRIVERS FOR THE INCREASED HEALTH CARE COSTS ASSOCIATED WITH PROSTATE CANCER

    May 1, 2009, 00:00

  • PHP7 ABOLITION OF PRESCRIPTION CO-PAYMENTS- AN ANALYSIS OF ITEMS DISPENSED IN WALES

    May 1, 2009, 00:00

  • PMS7 A 2-YEAR EVALUATION OF INFLIXIMABS EFFECTIVENESS IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN ACTUAL PRACTICE

    May 1, 2009, 00:00

  • PMH87 TREATMENT PATTERNS BY RACE/ETHNICITY AND INCOME LEVELS AMONG ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) SUBJECTS TREATED WITH SHORT-, INTERMEDIATE-AND LONG-ACTING STIMULANTS

    May 1, 2009, 00:00

  • PMC7 EFFECTS OF HETEROGENEITY ON THE ESTIMATION AND COMPARISON OF MEDICATION ERROR RATES

    May 1, 2009, 00:00

  • CO1 EVIDENCE-BASED TIME HORIZON FOR THE INTERVENTIONS IN PHARMACOECONOMIC MODELS

    May 1, 2009, 00:00

  • PSS14 HEALTH RESOURCE USE DURING STAPLE REMOVAL FOLLOWING GRAFT FIXATION

    May 1, 2009, 00:00

  • PIN18 THE ESTABLISHMENT OF A COST-EFFECTIVE ANTIBIOTIC TREATMENT OF INFECTIVE ENDOCARDITIS AND MRSA BACTEREMIA IN MEXICAN PUBLIC HEALTH CARE SYSTEM

    May 1, 2009, 00:00

  • MD5 PREDICTORS OF ENROLLMENT IN MEDICARE PART D- ARE BENEFICIARIES RATIONAL?

    May 1, 2009, 00:00

  • PIN22 COST OF PNEUMOCOCCAL INFECTIONS AND COST-EFFECTIVENESS ANALYSIS OF PNEUMOCOCCAL VACCINATION IN TURKEY

    May 1, 2009, 00:00

  • PDB43 PATIENT REPORTED OUTCOMES ARE SUPERIOR IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH LIRAGLUTIDE AS COMPARED TO EXENATIDE, WHEN ADDED TO METFORMIN, SULFONYLUREA OR BOTH

    May 1, 2009, 00:00

  • PSY35 THE RELATIONSHIP BETWEEN QUALITY OF LIFE, DISABILITY AND PAIN IN PATIENTS WITH FAILED BACK SURGERY SYNDROME

    May 1, 2009, 00:00

  • PCN56 IMPACT OF BONE METASTASES (BM) ON HEALTH CARE COSTS BEFORE AND AFTER OCCURRENCE OF SKELETAL RELATED EVENTS (SRES) IN MEN WITH PROSTATE CANCER (PC)

    May 1, 2009, 00:00

  • PCN83 A MULTINATIONAL STUDY OF PATIENT PREFERENCE VALUES FOR HEALTH STATES FOR CHRONIC MYELOGENOUS LEUKEMIA

    May 1, 2009, 00:00

  • CN4 LEVERAGING MULTIPLE DATA SOURCES TO EVALUATE COST AND SURVIVAL IN FOLFOX OR FOLFIRI TREATED STAGE IV COLORECTAL CANCER PATIENTS

    May 1, 2009, 00:00

  • CO4 COMPARISON OF INPATIENT COST ESTIMATION METHODS- USING DATA FROM A CYSTIC FIBROSIS TRIAL

    May 1, 2009, 00:00

  • PGI17 EXAMINATION OF PROTON PUMP INHIBITOR (PPI) UTILIZATION AMONG GASTROESOPHAGEAL REFLUX (GERD) PATIENTS USING ELECTRONIC MEDICAL RECORDS (EMR)

    May 1, 2009, 00:00

  • PCV61 MEDICAL EXPENDITURES ATTRIBUTABLE TO CORONARY ARTERY DISEASE IN THE UNITED STATES

    May 1, 2009, 00:00

  • PUK2 RESTRICTED ACCESS TO DRUGS IS ASSOCIATED WITH LESS OPTIMAL MINERAL METABOLISM CONTROL IN HEMODIALYSIS PATIENTS

    May 1, 2009, 00:00

  • PMH51 PSYCHOMETRIC PROPERTIES OF THE LIFE PARTICIPATION SCALE FOR ADULTS ASSESSING DEFICITS IN ADAPTIVE FUNCTIONING

    May 1, 2009, 00:00

  • PDB42 PERCEPTION VERSUS REALITY-CATEGORISATION OF PATIENT WEIGHT BY TYPE 2 DIABETES (T2DM) PATIENTS AND THEIR PHYSICIANS IN THE US AND EUROPE

    May 1, 2009, 00:00

  • PIN42 ANALYZING INPATIENT DATA FOR HEPATITIS PATIENTS

    May 1, 2009, 00:00

  • PCV12 FONDAPARINUX IS ECONOMICALLY NON-INFERIOR TO ENOXAPARIN FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM

    May 1, 2009, 00:00

  • PMH17 HEALTH CARE COSTS ASSOCIATED WITH TREATMENT OF BIPOLAR DISORDER USING A MOOD STABILIZER PLUS ADJUNCTIVE ARIPIPRAZOLE, QUETIAPINE, RISPERIDONE, OLANZAPINE OR ZIPRASIDONE

    May 1, 2009, 00:00

  • UT4 SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES- IS IT TIME TO CALL 'TIMEOUT' ON TTO?

    May 1, 2009, 00:00

  • PMS13 PREVALENCE OF FIBROMYALGIA IN RUSSIA

    May 1, 2009, 00:00

  • PHP3 HEALTH CARE PATTERNS AND PATIENT SATISFACTION IN EUROPE- A COMPARISON OF SIX COUNTRIES

    May 1, 2009, 00:00

  • PHP13 COST-RELATED UNDERUSE OF MEDICINE DUE TO MEDICAID PHARMACY COST-CONTAINMENT POLICY ACTIONS

    May 1, 2009, 00:00

  • PCN31 COST OF CARE FOR MEDICARE PATIENTS DIAGNOSED WITH METASTATIC BREAST CANCER WHO RECEIVED TRASTUZUMAB

    May 1, 2009, 00:00

  • PCN101 BREAST CANCER SCREENING OR DIAGNOSTIC PROCEDURES IN POSTMENOPAUSAL WOMEN INITIATING OSTEOPOROSIS MEDICATIONS

    May 1, 2009, 00:00

  • PMC30 USING AN ENCOUNTER-BASED DATABASE TO VALIDATE A DISEASE PROGRESSION MODEL- LESSONS FOR MODELERS

    May 1, 2009, 00:00

  • PUK12 CLINICAL AND ECONOMIC EVALUATION OF OVERACTIVE BLADDER PATIENTS (OAB) FAILLING TO CONSERVATIVE MANAGEMENT IN SPAIN- A FOUR HOSPITAL BASED ECONOMIC MODEL

    May 1, 2009, 00:00

  • PUK11 AN ECONOMIC EVALUATION OF FESOTERODINE IN THE TREATMENT OF OVERACTIVE BLADDER (OAB) IN KOREA

    May 1, 2009, 00:00

  • DB4 COST OF DIABETIC-RELATED COMPLICATIONS AND CARDIOVASCULAR EVENTS BY TYPE OF EVENT AND SETTING ANNUALLY FOR THE FIRST THREE YEARS FOLLOWING ITS ONSET

    May 1, 2009, 00:00

  • PDB1 LITERATURE REVIEW OF THE IMPACT OF OBESITY ON CARDIOVASCULAR OUTCOMES IN THE GENERAL POPULATION AND IN PATIENTS WITH TYPE-2 DIABETES

    May 1, 2009, 00:00

  • MS3 THE IMPACT OF COMPLIANCE WITH BIOLOGIC THERAPY ON CLINICAL OUTCOMES IN PATIENTS WITH RHEUMATOID ARTHRITIS

    May 1, 2009, 00:00

  • PHP83 WHAT IS THE FUTURE IN THE IMPLEMENTATION OF HEALTH TECHNOLOGIES IN THE PUBLIC SECTOR IN SPAIN? A QUALITATIVE STUDY EXPLORING KEY DECISION-MAKERS PERSPECTIVES

    May 1, 2009, 00:00

  • PND35 SOCIOECONOMIC FACTORS OF INSOMNIA PRESCRIPTION IN A NATIONAL DATABASE

    May 1, 2009, 00:00

  • CASE5 HARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT- A CASE STUDY OF ERLOTINIB AT A MAJOR CANCER CENTER

    May 1, 2009, 00:00

  • PMH59 THE IMPACT OF THE FDA ANTIDEPRESSANT BLACK BOX WARNING ON THE CONTINUITY OF ANTIDEPRESSANT TREATMENT IN CHILDREN WITH DEPRESSION

    May 1, 2009, 00:00

  • PND38 EMPIRICAL CLASSIFICATION OF EPILEPSY TYPES IN INSURANCE CLAIMS DATA

    May 1, 2009, 00:00

  • PMC77 DEVELOPMENT AND VALIDATION OF AN E-PRO TEMPLATE ADMINISTERED VIA A WEB-BASED INTERFACE

    May 1, 2009, 00:00

  • PHP38 THE POWER OF EPIDEMIOLOGICAL ESTIMATORS TO RATE INEQUALITIES IN HEALTH IN HIGH-INCOME OECD COUNTRIES, 1998-2002

    May 1, 2009, 00:00

  • PCV63 INPATIENT BURDEN OF ILLNESS AND PREDICTORS OF CHARGES OR LENGTHS OF STAY AMONG ADULT HEART TRANSPLANTATION PATIENTS

    May 1, 2009, 00:00

  • PCASE2 THE HOSPITAL AS IMPORTANT SOURCE OF INFORMATION REGARDING CHARACTERISTICS OF HEALTH CARE USERS

    May 1, 2009, 00:00

  • PIN36 THE ECONOMIC IMPACT OF MARAVIROC FOR ANTIRETROVIRAL TREATMENT-EXPERIENCED HIV-INFECTED INDIVIDUALS IN MEXICO

    May 1, 2009, 00:00

  • PHP49 THE CHANGING DYNAMICS IN HEALTH CARE FUNDING

    May 1, 2009, 00:00

  • PMC66 USE OF THE MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW (M.I.N.I.) - VERSION 6 - IN AN INTERNATIONAL STUDY

    May 1, 2009, 00:00

  • PCV18 ADHERENCE TO STATIN TREATMENT AND ACHIEVING LOW DENSITY LIPOPROTEIN CHOLESTEROL (LDL-C) GOALS IN AN EMPLOYEE POPULATION

    May 1, 2009, 00:00

  • PCV43 WHICH PUBLIC POLICY IS MORE COST-EFFECTIVE IN REDUCING CARDIAC DEATHS- INCREASED TAXES OR SMOKING BANS?

    May 1, 2009, 00:00

  • PIN54 INCREASING CHC TREATMENT RATE IN US IS A COST-SAVING STRATEGY

    May 1, 2009, 00:00

  • PMH2 USE OF HYPNOTICS/ANXIOLYTICS IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER- ASSOCIATIONS WITH CHRONIC PAIN, SLEEP DISORDERS, AND ANTIDEPRESSANT SELECTION

    May 1, 2009, 00:00

  • PIN33 COST EFFECTIVENESS OF SWITCHING TO SECOND LINE THERAPY WITH LOPINAVIR/RITONAVIR (LPV/R) IN KENYA

    May 1, 2009, 00:00

  • CASE6 PILOT PROJECT- INTEGRATING ADMINISTRATIVE AND FINANCIAL DATABASES TO ESTIMATE PRICE OF HOSPITALIZATIONS

    May 1, 2009, 00:00

  • PND34 DISEASE BURDEN AND TREATMENT PATTERNS OF PARKINSONS DISEASE IN A LONG TERM CARE SETTING

    May 1, 2009, 00:00

  • PIH5 AN ANALYSIS OF SELECT INJURY-INCREASING ANALGESIC MEDICATIONS IN MEDICARE DUAL ELIGIBLE ENROLLEES

    May 1, 2009, 00:00

  • PMS58 FIBROMYALGIA- RUSSIAN RHEUMATOLOGISTS DISEASE MANAGEMENT

    May 1, 2009, 00:00

  • PDB33 DAILY AVERAGE CONSUMPTION OF BASAL INSULIN IN PATIENTS WITH TYPE 2 DIABETES

    May 1, 2009, 00:00

  • PSY13 FREQUENCY AND BOTHERSOMENESS OF SIDE EFFECTS IN PAIN PATIENTS TAKING OXYCODONE IMMEDIATE RELEASE- IMPACT ON PRESCRIPTION AND OVER-THE-COUNTER MEDICATION USE

    May 1, 2009, 00:00

  • PCV87 IS MEASURING HEALTH STATUS BENEFICIAL IN HEART FAILURE PATIENTS?

    May 1, 2009, 00:00

  • PHP16 MARKET DISCONTINUATION OF PHARMACEUTICALS IN THE UNITED STATES- ANALYSIS OF DRUGS APPROVED BY THE FDA FROM 1939 TO 2008

    May 1, 2009, 00:00

  • PHP2 PHARMACY BENEFIT DESIGN AND PATIENT DRUG SUBSTITUTION

    May 1, 2009, 00:00

  • PDB26 RACE AND GENDER DIFFERENCES IN ECONOMIC BURDEN OF DIABETES HOSPITALIZATIONS IN TENNESSEE

    May 1, 2009, 00:00

  • HT3 A FRAMEWORK FOR DERIVING A MINIMALLY ACCEPTABLE TARGET CLINICAL PROFILE AND A MAXIMUM VALUE-BASED PRICE FOR DRUGS IN DEVELOPMENT TO MEET HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS

    May 1, 2009, 00:00

  • PMC62 ASSESSING THE QUALITY OF CONJOINT ANALYSIS APPLICATIONS IN HEALTH- A PILOT EVALUATION OF THE ISPOR CHECKLIST FOR GOOD RESEARCH PRACTICE IN CONJOINT ANALYSIS

    May 1, 2009, 00:00

  • PMH30 HOSPITALIZATION COSTS FOR SCHIZOPHRENIA RELAPSES IN A PUBLIC PSYCHIATRIC INSTITUTION

    May 1, 2009, 00:00

  • PSY49 DETERMINANTS OF MEDICAL SERVICES UTILIZATION IN CHRONIC NONCANCER PAIN PATIENTS

    May 1, 2009, 00:00

  • PM1 PERSONALIZED MEDICINE- FACTORS INFLUENCING REIMBURSEMENT

    May 1, 2009, 00:00

  • PM2 IMPACT OF PHARMACOGENETICS ON THE COSTS OF MANAGING ADVERSE EVENTS WITH WARFARIN- A PROSPECTIVE ANALYSIS

    May 1, 2009, 00:00

  • PCN73 USING SHORT-TERM RESPONSE TO PREDICT LONG-TERM OUTCOMES IN PATIENTS WITH IMATINIB-RESISTENT OR IMATINIB-INTOLERANT CHRONIC MYELOID LEUKAEMIA

    May 1, 2009, 00:00

  • HM3 IMPACT OF A SPECIALTY CARE MANAGEMENT PROGRAM ON MEDICATION ADHERENCE AND HEALTH CARE UTILIZATION AMONG NON-ELDERLY ADULTS WITH MULTIPLE SCLEROSIS

    May 1, 2009, 00:00

  • PIH32 THE BRAZILIAN PORTUGUESE VALIDATION OF THE PROLAPSE-QUALITY OF LIFE QUESTIONNAIRE-P-QOL

    May 1, 2009, 00:00

  • PCN13 THE PREVALENCE AND COSTS OF ADVERSE METABOLIC EFFECTS OF ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS

    May 1, 2009, 00:00

  • PCN66 COST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY AMONG U.S. BREAST CANCER PATIENTS

    May 1, 2009, 00:00

  • PIH45 THE IMPACT OF MEDICARE PART D ON HEALTH CARE UTILIZATION AND HEALTH OUTCOMES FOR MEDICARE BENEFICIARIES WITHOUT PREVIOUS DRUG COVERAGE

    May 1, 2009, 00:00

  • CM3 THE IMPACT OF MEDICARE PART D ON ELDERLY PATIENTS COMPLIANCE WITH STATINS

    May 1, 2009, 00:00

  • PRS41 APPROPRIATE USE OF INHALED CORTICOSTEROID AND LONG-ACTING -AGONIST COMBINATION THERAPY AMONG ASTHMA PATIENTS

    May 1, 2009, 00:00

  • PCV44 COST EFFECTIVENESS OF CLOPIDOGREL TREATMENT VERSUS ASPIRIN TREATMENT IN SOUTH KOREAN PATIENTS WITH ATHEROTHROBOSIS- RESULTS OF THE CAPRIE (CLOPIDOGREL VERSUS ASPIRIN IN PATIENTS AT RISK OF ISCHEMIC EVENTS) STUDY

    May 1, 2009, 00:00

  • PMC4 A FRAMEWORK FOR DEVELOPING A FLEXIBLE CONTROL-BASED ASTHMA POLICY MODEL

    May 1, 2009, 00:00

  • PCV3 MEDIATING ROLE OF CEREBROVASCULAR DISEASE IN THE ASSOCIATION BETWEEN DIABETES MELLITUS AND DEMENTIA

    May 1, 2009, 00:00

  • PHP26 THE IMPACT OF MEDICARE PART D ON MEDICARE-MEDICAID DUAL-ELIGIBLE BENEFICIARIES PRESCRIPTION UTILIZATION AND EXPENDITURES

    May 1, 2009, 00:00

  • PCN45 PHARMACOECONOMIC EVALUATION OF THE USE OF SOMATOSTATIN ANALOGS HANDLING THE ASSOCIATED SYMPTOMS OF CARCINOID SYNDROME

    May 1, 2009, 00:00

  • PMC84 THE POWER OF ASSUMPTIONS

    May 1, 2009, 00:00

  • PCV92 HOW DOES THE OUT-OF-POCKET PAYMENT MATTER TO HYPERTENSIVE PATIENTS CHOICES OF ACCESSING DIFFERENT MEDICAL FACILITIES IN TAIWAN? THE PRELIMINARY STUDY OF A DISCRETE CHOICE EXPERIMENT

    May 1, 2009, 00:00

  • PMS18 ESTIMATION OF COSTS RELATED TO ADVERSE EVENTS IN NSAID TREATMENT OF OSTEOARTHRITIS - A COMPARISON BETWEEN CELECOXIB AND IBUPROFEN USING A VALIDATED MODEL

    May 1, 2009, 00:00

  • PCN40 A COST-EFFECTIVENESS ANALYSIS OF BENDAMUSTINE AT A TERTIARY CANCER CENTER

    May 1, 2009, 00:00

  • PMC24 A PREDICTION MODEL TO IDENTIFY SUBJECTS WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) FROM A MANAGED CARE ADMINISTRATIVE CLAIMS DATABASE

    May 1, 2009, 00:00

  • PHP59 INCIDENCE AND OUTCOMES OF POTENTIAL DRUG-DRUG INTERACTIONS AMONG MEDICARE PART D PATIENTS

    May 1, 2009, 00:00

  • PMC88 AN EXPLORATORY ANALYSIS OF REASONS BEHIND PREMATURE TERMINATION OF RANDOMIZED CONTROLLED TRIALS

    May 1, 2009, 00:00

  • PRS45 SMOKING-ATTRIBUTABLE BURDEN OF FOUR TOBACCO-RELATED DISEASES IN COLOMBIA IN 2007

    May 1, 2009, 00:00

  • FD3 CONCEPTUAL ISSUES IN THE DEVELOPMENT OF A MEASURE OF FORMULARY CULTURE

    May 1, 2009, 00:00

  • PMC57 RELATIONSHIP BETWEEN QUALITY OF LIFE AND HEALTH-RELATED MEASURES INCLUDING SYMPTOMS, BIOCHEMICAL MARKERS AND TUMOR BURDEN

    May 1, 2009, 00:00

  • PCV95 ELECTRONIC MEDICAL RECORD USE AND WARFARIN DRUG-DRUG INTERACTIONS DURING AMBULATORY VISITS IN THE UNITED STATES, 2003-2006

    May 1, 2009, 00:00

  • PIN49 NEW ANTIFUNGAL MEDICATION IMPACT ON MARKET SHARE AND UTILIZATION OF TRADITIONAL AGENTS IN A SINGLE HEALTH CARE SYSTEM

    May 1, 2009, 00:00

  • PMH5 PATIENT ASSESSED QUALITY OF LIFE VERSUS CLINICIAN ASSESSMENT- A POST-HOC ANALYSIS OF A TRIAL OF ARIPIPRAZOLE IN ADOLESCENT PATIENTS WITH SCHIZOPHRENIA

    May 1, 2009, 00:00

  • PND9 IS GENETIC TESTING IN COMBINATION WITH PREVENTIVE DONEPEZIL (ARICEPT) TREATMENT FOR PATIENTS WITH MILD COGNITIVE IMPAIRMENT COST- EFFECTIVE?

    May 1, 2009, 00:00

  • PND30 DATA ANALYSIS OF PEDIATRIC INPATIENTS DIAGNOSED WITH BRAIN ABSCESS

    May 1, 2009, 00:00

  • PCN64 THE ECONOMIC BURDEN ASSOCIATED WITH METASTATIC COLORECTAL CANCER

    May 1, 2009, 00:00

  • PMC42 FINITE MIXTURE REGRESSIONS IN MODELING PRESCRIPTION DRUG UTILIZATION AND PRESCRIPTION DRUG EXPENDITURES OF PATIENTS WITH REUMATOID ARTHRITIS (RA)

    May 1, 2009, 00:00

  • PMS33 BURDEN OF ILLNESS OF CONSERVATIVE MEDICAL MANAGEMENT OF OSTEOPOROTIC VERTEBRAL COMPRESSION FRACTURES IN JAPAN

    May 1, 2009, 00:00

  • PCN39 COST-EFFECTIVENESS ANALYSIS OF LUNG CANCER SCREENING WITH COMPUTED TOMOGRAPHY

    May 1, 2009, 00:00

  • PMC11 GROWTH, CHARACTERISTICS AND QUALITY OF THE COST-UTILITY ANALYSIS LITERATURE THROUGH 2006

    May 1, 2009, 00:00

  • PMC21 DOES VARYING SELECTION BIAS CORRECTION TECHNIQUE MATTER IN ESTIMATION OF TREATMENT EFFECTS IN PRESENCE OF MULTIPLE ENDOGENOUS TREATMENTS?

    May 1, 2009, 00:00

  • PIN35 COST-EFFECTIVENESS OF MARAVIROC FOR HIV IN MEXICO

    May 1, 2009, 00:00

  • CASE4 DIABETES PHYSICIAN RECOGNITION IN A LARGE HEALTH PLAN

    May 1, 2009, 00:00

  • PSS3 USING 'NUMBER NEEDED TO TREAT' TO HELP CONCEPTUALIZE THE MAGNITUDE OF BENEFIT AND RISK OF TNF INHIBITORS FOR PATIENTS WITH SEVERE PSORIASIS

    May 1, 2009, 00:00

  • PCN1 TIME DELAY OF OCCURRENCE OF SECONDARY MALIGNANT TUMORS AFTER PRIMARY BREAST CANCER IN THE FEMALE POPULATION OF HUNGARY BETWEEN 2003 AND 2007

    May 1, 2009, 00:00

  • PMC70 VALUING HEALTH FROM SCRATCH- THE APPLICATION OF COMMONSENSE PRINCIPLES TO THE DESIGN OF HEALTH STATE VALUATION METHODS

    May 1, 2009, 00:00

  • PIN6 A DATA ANALYSIS OF INPATIENTS AFFECTED BY THE HUMAN PAPILLOMAVIRUS

    May 1, 2009, 00:00

  • PMC45 EXTENDING RANDOM EFFECT MODELS TO CENSORED COST DATA

    May 1, 2009, 00:00

  • PMC56 THE EFFECT OF RECALL PERIOD ON CANCER PATIENTS RATINGS OF THE SEVERITY OF MULTIPLE SYMPTOMS

    May 1, 2009, 00:00

  • PDB12 RISK FACTORS FOR DEMENTIA IN ELDERLY PATIENTS WITH DIABETES MELLITUS

    May 1, 2009, 00:00

  • PHP84 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION ACROSS FOUR HEALTH TECHNOLOGY APPRAISAL SYSTEMS CATEGORISED BY DISEASE

    May 1, 2009, 00:00

  • PRS6 ESTIMATION OF QUALITY-ADJUSTED LIFE EXPECTANCY AND LOSS OF UTILITY IN PATIENTS UNDER PROLONGED MECHANICAL VENTILATION

    May 1, 2009, 00:00

  • PCN70 MODELLING THE COST EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES VERSUS IRINOTECAN AND INFUSIONAL FLUOROPYRIMIDINES IN METASTATIC COLORECTAL CANCER PATIENTS IN SWED ...

    May 1, 2009, 00:00

  • PHC7 DEVELOPMENT AND VALIDATION OF SPECIFIC HEALTH RELATED QUALITY OF LIFE QUESTIONNAIRE FOR HALITOSIS- THE HALITOSIS QUALITY OF LIFE QUESTIONNAIRE (HQLQ)

    May 1, 2009, 00:00

  • PCN62 FIRST YEAR COST EXPENDITURES ASSOCIATED WITH HEAD AND NECK CANCER DIAGNOSIS IN THE U.S. MANAGED CARE POPULATION

    May 1, 2009, 00:00

  • PC4V19 EFFECT OF ACE INHIBITORS/ARBS AND STATINS ON THE INCIDENCE OF DEMENTIA, IN PATIENTS WITH CHRONIC HEART FAILURE

    May 1, 2009, 00:00

  • PSY43 USE OF PRESCRIPTION PHARMACOTHERAPY IN PATIENTS WITH FIBROMYALGIA - EVIDENCE OF UNMET NEEDS?

    May 1, 2009, 00:00

  • CV1 COMPARISON OF CARDIOVASCULAR EVENT RATES IN SUBJECTS WITH TYPE-2 DIABETES MELLITUS WHO AUGMENTED FROM STATIN MONOTHERAPY TO STATIN PLUS FIBRATE COMBINATION THERAPY WITH THOSE WHO REMAINED ON STATIN MONOTHERAPY

    May 1, 2009, 00:00

  • PIH10 COST EFFECTIVENESS OF ORAL BISPHOSPHONATES ADMINISTERED ON EXTENDED DOSING INTERVALS

    May 1, 2009, 00:00

  • PUK13 COST-EFFECTIVENESS OF A RENAL HEALTH PROGRAM IN PATIENTS WITH HYPERTENSIVE AND/OR DIABETES INDUCED CHRONIC KIDNEY DISEASE

    May 1, 2009, 00:00

  • PHP82 USE OF INDIRECT COMPARISON IN HTA SUBMISSIONS

    May 1, 2009, 00:00

  • PCN53 COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINE FOR PREVENTION OF CERVICAL CANCER IN TAIWAN

    May 1, 2009, 00:00

  • PMH37 DISCRETE EVENT SIMULATION COMPARING QUALITY OF LIFE AND COSTS BETWEEN OLANZAPINE AND QUETIAPINE XR TREATMENT FOR SCHIZOPHRENIA IN MEXICO

    May 1, 2009, 00:00

  • PSY29 VARIABILITY OF FEES IN THE FIELD OF HAEMOGRAMS IN THE AUSTRIAN CONTRACT PHYSICIANS SECTOR

    May 1, 2009, 00:00

  • PDB17 GLYCEMIC VARIABILITY AND COMPLICATIONS IN PATIENTS WITH DIABETES MELLITUS- EVIDENCE FROM A SYSTEMATIC REVIEW OF THE LITERATURE

    May 1, 2009, 00:00

  • PND42 BRAZILIAN NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS (MS)- AN EXPLORATORY STUDY ABOUT THE IMPACT OF THE PATIENTS ADHERENCE IN THE TREATMENT COSTS

    May 1, 2009, 00:00

  • PIH4 PERSONALIZED MEDICINE- TRENDS IN CLINICAL STUDIES BASED ON NATIONAL REGISTRY DATA

    May 1, 2009, 00:00

  • PCV91 DISPARITIES IN CORONARY ARTERY DISEASE CARE AMONG ENROLLEES WITH AARP MEDICARE SUPPLEMENT INSURANCE

    May 1, 2009, 00:00

  • PCN68 COST-EFFECTIVENESS OF CETUXIMAB (ERBITUXTM) FOR THE FIRST LINE TREATMENT OF SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN) IN CANADA

    May 1, 2009, 00:00

  • DU3 PATTERN OF UTILIZATION OF PEGFILGRASTIM IN PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA- A RETROSPECTIVE ANALYSIS OF ADMINISTRATIVE CLAIMS DATA

    May 1, 2009, 00:00

  • PSS16 CHARACTERIZING FUNCTIONAL LIMITATIONS FOR ADULTS WITH DIABETIC RETINOPATHY

    May 1, 2009, 00:00

  • PIH39 ASSOCIATION BETWEEN SEXUAL DRIVE CHANGE AND PREMENSTRUAL SYMPTOMS

    May 1, 2009, 00:00

  • PMH84 AN ASSESSMENT OF THE IMPACT OF AN EDUCATIONAL PHARMACY MANAGEMENT INTERVENTION ON PRESCRIBERS TO MEDICAID BENEFICIARIES

    May 1, 2009, 00:00

  • PCV109 THERAPY INTERRUPTIONS IN PATIENTS SWITCHED FROM BRANDED TO OTHER GENERIC STATINS

    May 1, 2009, 00:00

  • PMH72 IMPACT OF PHARMACY BENEFIT DESIGN ON ANTI-PSYCHOTIC MEDICATION ADHERENCE AND DISCONTINUATION

    May 1, 2009, 00:00

  • PCV77 EVALUATION OF AN EDUCATIONAL ANTIHYPERTENSIVE MEDICATION ADHERENCE TOOL- IMPACT ON ANTIHYPERTENSIVE ADHERENCE AND BLOOD PRESSURE CONTROL

    May 1, 2009, 00:00

  • PIN45 EMPLOYEES WILLINGNESS TO PAY FOR INFLUENZA VACCINATION OF HOUSEHOLD MEMBERS-RESULTS FROM THE CHILD AND HOUSEHOLD INFLUENZA-ILLNESS AND EMPLOYEE FUNCTION (CHIEF) STUDY

    May 1, 2009, 00:00

  • PRS35 PREVALENCE OF ASTHMA, DIABETES MELLITUS AND ESSENTIAL HYPERTENSION AND ASSOCIATION OF HEALTH INSURANCE WITH BRAND STATUS OF DIAGNOSIS SPECIFIC PRESCRIPTION DRUGS

    May 1, 2009, 00:00

  • PCN90 A METHODOLOGICAL INVESTIGATION TO DEFINE A CLINICALLY RELEVANT CUT-OFF POINT IN THE ORDINAL SCALE OF THE EORTC QLQ-C30 QUESTIONNAIRE

    May 1, 2009, 00:00

  • PIH37 URINARY URGENCY INTENSITY RATING IN RELATION TO SYMPTOM FREQUENCY, BOTHER, AND TREATMENT SEEKING- RESULTS FROM EPILUTS IN THE US, UK, AND SWEDEN (SE)

    May 1, 2009, 00:00

  • PMH26 THE COST BURDEN OF TREATMENT RESISTANCE IN PATIENTS WITH DEPRESSION

    May 1, 2009, 00:00

  • Prescribing Trends and Drug Budget Impact of the ARBs in the UK

    Mar 1, 2009, 00:00

  • FDAMA 1997 Section 114- Another Look

    Mar 1, 2009, 00:00

  • Who Does the Numbers? The Role of Third-Party Technology Assessment to Inform Health Systems' Decision-Making about the Funding of Health Technologies

    Mar 1, 2009, 00:00

  • What Ever Happened to FDAMA Section 114? A Look back after 10 Years

    Mar 1, 2009, 00:00

  • Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy

    Mar 1, 2009, 00:00

  • The Costs of Care in Atrial Fibrillation and the Effect of Treatment Modalities in Germany

    Mar 1, 2009, 00:00

  • Cost Impact of Diagnostic Imaging for Lower Extremity Peripheral Vascular Occlusive Disease

    Mar 1, 2009, 00:00

  • QALYs- Some Challenges

    Mar 1, 2009, 00:00

  • Economic Evaluation of the Decisions of the Israeli Public Committee for Updating the National List of Health Services in 2006/2007

    Mar 1, 2009, 00:00

  • Economic Evaluation of Influenza Pandemic Mitigation Strategies in the United States Using a Stochastic Microsimulation Transmission Model

    Mar 1, 2009, 00:00

  • A Different Approach to Health State Valuation

    Mar 1, 2009, 00:00

  • A Cost-Effectiveness Model Comparing Endovascular Repair to Open Surgical Repair of Abdominal Aortic Aneurysms in Canada

    Mar 1, 2009, 00:00

  • Editorial- Moving the QALY Forward or Just Stuck in Traffic?

    Mar 1, 2009, 00:00

  • Excessive Hospitalizations and Its Associated Economic Burden among People with Diabetes in the United States

    Mar 1, 2009, 00:00

  • The Health and Economic Consequences of Moderate Alcohol Consumption in Germany 2002

    Mar 1, 2009, 00:00

  • Information on Center Characteristics as Costs' Determinants in Multicenter Clinical Trials- Is Modeling Center Effect Worth the Effort?

    Mar 1, 2009, 00:00

  • What Outcomes Are Important to Patients with Long Term Conditions? A Discrete Choice Experiment

    Mar 1, 2009, 00:00

  • Retaining, and Enhancing, the QALY

    Mar 1, 2009, 00:00

  • Cost Analysis of Long-Term Treatment of Patients with Symptomatic Gastroesophageal Reflux Disease (GERD) with Esomeprazole On-Demand Treatment or Esomeprazole Continuous Treatment- An Open, Randomized, Multicenter Study in Switzerland

    Mar 1, 2009, 00:00

  • Moving the QALY Forward- Rationale for Change

    Mar 1, 2009, 00:00

  • Cost-Effectiveness of Testing for Breast Cancer Susceptibility Genes

    Mar 1, 2009, 00:00

  • Mapping the English and Chinese Versions of the Functional Assessment of Cancer Therapy–General to the EQ-5D Utility Index

    Mar 1, 2009, 00:00

  • Predicting the Short Form-6D Preference-Based Index Using the Eight Mean Short Form-36 Health Dimension Scores- Estimating Preference-Based Health-Related Utilities When Patient Level Data Are not Available

    Mar 1, 2009, 00:00

  • Comparing the Health Utilities Index Mark 3 (HUI3) with the Short Form-36 Preference-Based SF-6D in Chronic Kidney Disease

    Mar 1, 2009, 00:00

  • Editorial- On the Benefits of Modeling Using QALYs for Societal Resource Allocation- The Model Is the Message

    Mar 1, 2009, 00:00

  • A Longitudinal Evaluation of Health-Related Quality of Life of Patients with Parkinson's Disease

    Mar 1, 2009, 00:00

  • Further Validation and Responsiveness Assessment of the Herpes Outbreak Impact Questionnaire and Herpes Symptom Checklist

    Mar 1, 2009, 00:00

  • The Costs of Change- Direct Medical Costs of Solid Organ Transplantation in British Columbia, Canada, 1995–2003

    Mar 1, 2009, 00:00

  • Modeling Length of Stay in Hospital and Other Right Skewed Data- Comparison of Phase-Type, Gamma and Log-Normal Distributions

    Mar 1, 2009, 00:00

  • Value of Information and Value of Implementation- Application of an Analytic Framework to Inform Resource Allocation Decisions in Metastatic Hormone-Refractory Prostate Cancer

    Mar 1, 2009, 00:00

  • QALYs- The Basics

    Mar 1, 2009, 00:00

  • Does Attribute Framing in Discrete Choice Experiments Influence Willingness to Pay? Results from a Discrete Choice Experiment in Screening for Colorectal Cancer

    Mar 1, 2009, 00:00

  • Cost-Effectiveness Evaluation of Ertapenem versus Piperacillin/Tazobactam in the Treatment of Complicated Intraabdominal Infections Accounting for Antibiotic Resistance

    Mar 1, 2009, 00:00

  • Cross-Cultural Validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS) in Four Latin American Countries

    Mar 1, 2009, 00:00

  • Toward a Consensus on the QALY

    Mar 1, 2009, 00:00

  • Health Utilities in Patients with HIV/AIDS in Thailand

    Mar 1, 2009, 00:00

  • The Use of QALYs in Clinical and Patient Decision-Making- Issues and Prospects

    Mar 1, 2009, 00:00

  • Mapping Utility Scores from a Disease-Specific Quality-of-Life Measure in Bariatric Surgery Patients

    Mar 1, 2009, 00:00

  • Development of a New Questionnaire to Assess Patient Perceptions of Cancer-Related Fatigue- Item Generation and Item Reduction

    Jan 1, 2009, 00:00

  • Evaluation of an Internet-Based Disease Trajectory Decision Tool for Prostate Cancer Screening

    Jan 1, 2009, 00:00

  • Validation of Gastrointestinal Quality of Life Index in Swedish for Assessing the Impact of Gallstones on Health-Related Quality of Life

    Jan 1, 2009, 00:00

  • The Health Value and Cost of Care for Major Depression

    Jan 1, 2009, 00:00

  • Cost-Effectiveness of Treatments Reducing Coronary Heart Disease Mortality in Ireland, 2000 to 2010

    Jan 1, 2009, 00:00

  • Breaking the Silence- Exploring the Potential Effects of Explicit Instructions on Incorporating Income and Leisure in TTO Exercises

    Jan 1, 2009, 00:00

  • Utility Estimates for Decision–Analytic Modeling in Chronic Heart Failure—Health States Based on New York Heart Association Classes and Number of Rehospitalizations

    Jan 1, 2009, 00:00

  • The Effects of Laparoscopic Surgery and Nosocomial Infections on the Cost of Care- Evidence from Three Common Surgical Procedures

    Jan 1, 2009, 00:00

  • An Empiric Estimate of the Value of Life- Updating the Renal Dialysis Cost-Effectiveness Standard

    Jan 1, 2009, 00:00

  • Budgetary Impact of Varenicline in Smoking Cessation in the United Kingdom

    Jan 1, 2009, 00:00

  • Estimating Clinically Meaningful Changes for the Functional Assessment of Cancer Therapy—Prostate- Results from a Clinical Trial of Patients with Metastatic Hormone-Refractory Prostate Cancer

    Jan 1, 2009, 00:00

  • Using Conjoint Analysis to Estimate Healthy-Year Equivalents for Acute Conditions- An Application to Vasomotor Symptoms

    Jan 1, 2009, 00:00

  • The Development of the Herpes Symptom Checklist and the Herpes Outbreak Impact Questionnaire

    Jan 1, 2009, 00:00

  • Reliability of the Discrete Choice Experiment at the Input and Output Level in Patients with Rheumatoid Arthritis

    Jan 1, 2009, 00:00

  • Prevention and Management of Hyperphosphatemia with Sevelamer in Canada- Health and Economic Consequences

    Jan 1, 2009, 00:00

  • Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument

    Jan 1, 2009, 00:00

  • Mapping the EORTC QLQ C-30 onto the EQ-5D Instrument- The Potential to Estimate QALYs without Generic Preference Data

    Jan 1, 2009, 00:00

  • Potential for Cost-Savings in the Care of Hospitalized Low-Risk Community-Acquired Pneumonia Patients in China

    Jan 1, 2009, 00:00

  • Estimating a Preference-Based Single Index from the Overactive Bladder Questionnaire

    Jan 1, 2009, 00:00

  • Long-Term Cost-Effectiveness of Pioglitazone versus Placebo in Addition to Existing Diabetes Treatment- A US Analysis Based on PROactive

    Jan 1, 2009, 00:00

  • Development and Evaluation of the Adherence to Refills and Medications Scale (ARMS) among Low-Literacy Patients with Chronic Disease

    Jan 1, 2009, 00:00

  • ISPOR Code of Ethics

    Jan 1, 2009, 00:00

  • Deterministic Sensitivity Analysis for First-Order Monte Carlo Simulations- A Technical Note

    Jan 1, 2009, 00:00

  • Gaining Efficiencies- Resources and Demand for Dialysis around the Globe

    Jan 1, 2009, 00:00

  • The Burden of Migraine in the United States- Current and Emerging Perspectives on Disease Management and Economic Analysis

    Jan 1, 2009, 00:00

  • Health State Valuation Methods and Reference Points- The Case of Tinnitus

    Jan 1, 2009, 00:00

  • Ultrasound-Guided Central Line Placement as Compared with Standard Landmark Technique- Some Unpleasant Arithmetic for the Economics of Medical Innovation

    Jan 1, 2009, 00:00

  • The Potential Clinical and Economic Outcomes of Pharmacogenomic Approaches to EGFR-Tyrosine Kinase Inhibitor Therapy in Non–Small-Cell Lung Cancer

    Jan 1, 2009, 00:00

  • The Impact of Proton Pump Inhibitor Compliance on Health-Care Resource Utilization and Costs in Patients with Gastroesophageal Reflux Disease

    Jan 1, 2009, 00:00

  • Economic Valuation of Informal Care- Conjoint Analysis Applied in a Heterogeneous Population of Informal Caregivers

    Dec 1, 2008, 00:00

  • Health State Utilities in Latent and Active Tuberculosis

    Dec 1, 2008, 00:00

  • Health State Utility Scores for Cancer-Related Anemia through Societal and Patient Valuations

    Dec 1, 2008, 00:00

  • Psychometric Equivalence of the OAB-q in Danish, German, Polish, Swedish, and Turkish

    Dec 1, 2008, 00:00

  • Estimation of Life Expectancy and the Expected Years of Life Lost in Patients with Major Cancers- Extrapolation of Survival Curves under High-Censored Rates

    Dec 1, 2008, 00:00

  • Reductions in Human Papillomavirus-Disease Resource Use and Costs with Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccination- The FUTURE Study Economic Evaluation

    Dec 1, 2008, 00:00

  • Expected Value of Perfect Information- An Empirical Example of Reducing Decision Uncertainty by Conducting Additional Research

    Dec 1, 2008, 00:00

  • Cost-Effectiveness of a Low-Calorie Diet and Orlistat for Obese Persons- Modeling Long-Term Health Gains through Prevention of Obesity-Related Chronic Diseases

    Dec 1, 2008, 00:00

  • Willingness to Accept versus Willingness to Pay in a Discrete Choice Experiment

    Dec 1, 2008, 00:00

  • Sociodemographic and Clinical Correlates of Utility Scores in Alzheimer's Disease

    Dec 1, 2008, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2008, 00:00

  • A Predictive Model of Health State Utilities for HIV Patients in the Modern Era of Highly Active Antiretroviral Therapy

    Dec 1, 2008, 00:00

  • “Price Management” and Its Impact on Hospital Pharmaceutical Expenditure and the Availability of Medicines in New Zealand Hospitals

    Dec 1, 2008, 00:00

  • Citizen's Preferences Regarding Principles to Guide Health-Care Allocation Decisions in Thailand

    Dec 1, 2008, 00:00

  • Hispanic Valuation of the EQ-5D Health States- A Social Value Set for Latin Americans

    Dec 1, 2008, 00:00

  • Deriving an Algorithm to Convert the Eight Mean SF-36 Dimension Scores into a Mean EQ-5D Preference-Based Score from Published Studies (Where Patient Level Data Are Not Available)

    Dec 1, 2008, 00:00

  • Balancing Equity and Efficiency in Health Priorities in Ghana- The Use of Multicriteria Decision Analysis

    Dec 1, 2008, 00:00

  • Drotrecogin Alfa's Impact on Intensive Care Workload in Real Life Practice- A Propensity Score Approach

    Dec 1, 2008, 00:00

  • Cost-Effectiveness of Preventing Hip Fractures by Hip Protectors in Elderly Institutionalized Residents in Germany

    Dec 1, 2008, 00:00

  • Discrete-Event Simulation Applied to Analysis of Waiting Lists. Evaluation of a Prioritization System for Cataract Surgery

    Dec 1, 2008, 00:00

  • Validity of the EuroQoL (EQ-5D) Instrument in a Greek General Population

    Dec 1, 2008, 00:00

  • Estimating Quality Weights for EQ-5D Health States with the Time Trade-Off Method in South Korea

    Dec 1, 2008, 00:00

  • Factors Associated with Variation in Utility Scores among Patients with Prostate Cancer

    Dec 1, 2008, 00:00

  • The Cost-Effectiveness of Atypicals in the UK

    Dec 1, 2008, 00:00

  • Statin Cost-Effectiveness Comparisons Using Real-World Effectiveness Data- Formulary Implications

    Dec 1, 2008, 00:00

  • PRS27 INTERPRETING SCORES ON THREE PATIENT-REPORTED OUTCOME MEASURES FOR ASTHMA

    Nov 1, 2008, 00:00

  • PIN37 GENITAL WARTS IN ITALY- A COST OF ILLNESS ANALYSIS

    Nov 1, 2008, 00:00

  • PDB57 EFFECT OF INSULIN GLARGINE OR NPH INSULIN ON TREATMENT SATISFACTION IN PATIENTS WITH TYPE 2 DIABETES MELLITUS

    Nov 1, 2008, 00:00

  • PDB54 PSYCHOLOGICAL INSULIN RESISTANCE (PIR)- PATIENT AND PHYSICIAN BELIEFS IMPACTING DIABETES MANAGEMENT

    Nov 1, 2008, 00:00

  • PRS24 QUALITY OF LIFE RESULTS USING THE EUROQOL QUESTIONNAIRES AND DIRECT MEDICAL COSTS IN ASTHMATIC PATIENTS. CHAS STUDY

    Nov 1, 2008, 00:00

  • PIN36 SOCIO-ECONOMIC IMPACT OF AVIAN INFLUENZA IN SOUTH-EAST ASIA AND NEIGHBOURING HIGH RISK COUNTRIES

    Nov 1, 2008, 00:00

  • PDB19 ESTIMATING THE COST EFFECTIVENESS IN THE UK OF VILDAGLIPTIN COMPARED TO PIOGLITAZONE AS ADD-ON THERAPY TO METFORMIN USING THE SHEFFIELD TYPE 2 DIABETES MODEL

    Nov 1, 2008, 00:00

  • PG132 CORRELATION BETWEENTHE SEVERITY OF UPPER GASTROINTESTINAL (GI) SYMPTOMS AND ENDOSCOPIC FINDINGS IN THE GREEK PRIMARY CARE SETTING

    Nov 1, 2008, 00:00

  • PSS28 VENOUS LEG ULCER. COSTS-OF-ILLNESS OF IN GERMANY. A NATIONAL CROSS-SECTIONAL STUDY

    Nov 1, 2008, 00:00

  • PCV118 ADVANCING SYNCOPE DIAGNOSISTHROUGH IMPLANTABLE LOOP RECORDERS (ILRS) IN SWEDEN- COST-EFFECTIVENESS ANALYSIS OF NEW DIAGNOSTIC STRATEGIES

    Nov 1, 2008, 00:00

  • PMS7 PREVALENCE OF FIBROMYALGIA- A LARGE-SCALE EUROPEAN SURVEY- EARLY RESULTS IN UNITED-KINGDOM

    Nov 1, 2008, 00:00

  • PCV35 COST-EFFECTIVENESS ANALYSIS OF STROKE REHABILITATION STRATEGIES IN EASTERN CHINA

    Nov 1, 2008, 00:00

  • PG140 PROTON PUMP INHIBITORS MARKET IN PRIMARY CARE SETTING

    Nov 1, 2008, 00:00

  • PCV41 COST EFFECTIVENESS OF IMPLANTABLE LOOP RECORDER SYSTEM (REVEAL DX) FROM THE SPANISH NHS PERSPECTIVE

    Nov 1, 2008, 00:00

  • PHP9 DELAY OF DECISION-MAKING ON PHARMACEUTICAL REIMBURSEMENT IN NORMAL PROCEDURE IN HUNGARY

    Nov 1, 2008, 00:00

  • PCN106 PROSTATE CANCER DIAGNOSIS IN SPAIN- HOW IS IT PERFORMED? HOW MUCH DOES IT COST FOR SPANISH NHS?

    Nov 1, 2008, 00:00

  • PSS11 SENSITIVE SKINS IN FRANCE- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • MH5 EFFECT OF A NURSE TELEPHONE FOLLOW-UP ON THERAPEUTIC ADHERENCE OF PATIENTS WITH SCHIZOPHRENIA

    Nov 1, 2008, 00:00

  • CN3 COST OF INITIAL PROSTATE CANCERTREATMENT FOLLOWING DIAGNOSIS PER PATIENT BY STAGE- ESTIMATES FROM THE UK, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PCN26 A COST-EFFECTIVENESS ANALYSIS OF XELOX AND FOLFOX-4 COMBINED WITH OR WITHOUT BEVACIZUMAB FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER IN SPAIN

    Nov 1, 2008, 00:00

  • PCN71 COST-EFFECTIVENESS OF ORALTOPOTECAN PLUS BEST SUPPORTIVE CARE VERSUS BEST SUPPORTIVE CARE ALONE IN PATIENTS WITH RELAPSED SMALL-CELL LUNG CANCER (SCLC) IN THE UK

    Nov 1, 2008, 00:00

  • IN4 ACHIEVING SUSTAINED VIROLOGIC RESPONSE WITH CHRONIC HEPATITIS CTREATMENT IS ASSOCIATED WITH IMMEDIATE HEALTH CARE UTILIZATION BENEFITS IN EUROPE

    Nov 1, 2008, 00:00

  • PMS54 RELIEF OF PAIN AND SYMPTOMS IN KNEE CARTILAGE DEFECT IS ASSOCIATED WITH HIGHER SF-36 UTILITY SCORES- DATA FROM A PROSPECTIVE RANDOMIZED TRIAL OF CHONDROCELECT

    Nov 1, 2008, 00:00

  • PDB31 THE COST OF TYPE 2 DIABETES MELLITUS IN CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PIH8 COST-EFFECTIVENESS OF PLANNED CAESAREAN SECTION VERSUS PLANNEDVAGINAL DELIVERY IN BREECH-PRESENTATION PREGNANCIES AT TERM

    Nov 1, 2008, 00:00

  • PG16 THE MANAGEMENT OF GASTRO OESOPHAGEAL REFLUX DISEASE IN SPAIN- A BUDGET IMPACT ANALYSIS TO ESTIMATE COSTS DUETO A GREATER PANTOPRAZOL IV PENETRATION

    Nov 1, 2008, 00:00

  • PSS41 USTEKINUMAB SIGNIFICANTLY IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2008, 00:00

  • PMC56 THE TRANSFERABILITY OF ECONOMIC EVALUATIONS. VALIDATING THE MODEL OF WELTE

    Nov 1, 2008, 00:00

  • PCV10 SUPERIOR FORGIVENESS WITH ALISKIREN IN THE PRESENCE OF IMPERFECT COMPLIANCE

    Nov 1, 2008, 00:00

  • PG126 DERIVING PREFERENCE BASED UTILITIES FOR CD AND UC PATIENTS- CONVERTING IBDQ INTO EQ-5D UTILITIES

    Nov 1, 2008, 00:00

  • PCN40 COST-EFFECTIVENESS OF TREATMENT WITH TRASTUZUMAB IN PATIENTS WITH EARLY BREAST CANCER FROM THE PORTUGUESE SOCIETAL PERSPECTIVE

    Nov 1, 2008, 00:00

  • PSY43 THE IMPACT OF ROMIPLOSTIM ON PATIENT-REPORTED OUTCOMES MEASURED BY THE EUROQOL (EQ-5D)

    Nov 1, 2008, 00:00

  • PRS23 IS THE EQ-5D RESPONSIVE TO RECOVERY FROM A MODERATE COPD EXACERBATION?

    Nov 1, 2008, 00:00

  • PSS15 SENSITIVE SKINS IN SPAIN- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PSY1 A SYSTEMATIC REVIEW OF THE EFFICACY OF RECOMBINANT ACTIVATED FACTORVII (RFVIIA) AND ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE (APCC) IN THE ON-DEMANDTREATMENT OF MINOR TO MODERATE BLEEDING EPISODES FOR HAEMOPHILIA PATIENTS WITH INHIBIT ...

    Nov 1, 2008, 00:00

  • PDB62 IMPACT OF INSURANCE PAYMENT SYSTEMS ON QUALITY OF CARE AND HEALTH CARE SERVICE UTILIZATION IN TYPE 2 DIABETES MEDICAID ENROLLEES

    Nov 1, 2008, 00:00

  • HT2 UPDATE OF RESULTS AND OUTCOMES OF NICE SINGLE TECHNOLOGY APPRAISALS-ECONOMIC CRITICISMS

    Nov 1, 2008, 00:00

  • PG125 ESTABLISHING THE RELATIONSHIP BETWEENTHE ULCERATIVE COLITIS DISEASE ACTIVITY INSTRUMENT (UCDAI) AND PATIENT HEALTH RELATED QUALITY OF LIFE FROM A LARGE RANDOMISED CONTROLLED TRIAL

    Nov 1, 2008, 00:00

  • PSS2 EFFECTIVENESS OF THE RESTOR MULTIFOCAL INTRAOCULAR LENS (IOL) IN CATARACT AND PRESBYOPIA SURGERIES IN TWO EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PDB38 THE COST-EFFECTIVENESS OF GROWTH HORMONE REPLACEMENTTHERAPY WITH GENOTROPIN IN HYPOPITUITARY ADULT PATIENTS

    Nov 1, 2008, 00:00

  • PHP30 COST DRIVERS IN THE PHARMACEUTICAL MARKET IN GERMANY IN 2007

    Nov 1, 2008, 00:00

  • PHP37 HEALTH EXPENDITURES AND PERFORMANCE.THE ANLISIS OF THE FINANCIAL GAPS IN BUENOS AIRES PROVINCE

    Nov 1, 2008, 00:00

  • PCN79 HEALTH STATE PREFERENCE STUDY MAPPING THE CHANGE OVER THE COURSE OF THE DISEASE PROCESS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL)

    Nov 1, 2008, 00:00

  • PCV1 THE ROLE OF LDL-LEVELS IN INITIATING STATIN TREATMENT

    Nov 1, 2008, 00:00

  • PMS22 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB IN THE TREATMENT OF ANKYLOSING SPONDYLITIS-COST EFFECTIVENESS ANALYSIS IN POLISH SETTINGS

    Nov 1, 2008, 00:00

  • PMC6 SOCIAL DISCOUNTING IN THE ECONOMIC EVALUATION OF HEALTH CARE PROGRAMMES

    Nov 1, 2008, 00:00

  • PSY6 PREDICTING FACTORS FOR METABOLIC SYNDROME FOR US ADOLESCENTS AGE 12-17

    Nov 1, 2008, 00:00

  • PMH58 BUDGET CONSTRAINTS AS A MAJOR CAUSE FOR UNDERTREATMENT OF PATIENTS SUFFERING FROM ALZHEIMERS DISEASE IN GERMANY- A COMPARATIVE PANEL SURVEY OF GENERAL PRACTIONERS AND NEUROLOGISTS

    Nov 1, 2008, 00:00

  • PCN36 PHARMACOECONOMIC COMPARISON OF TWO PROTOCOLS FACVS. CMF IN THE TREATMENT OF EARLY BREAST CANCER

    Nov 1, 2008, 00:00

  • PHP46 CATEGORISING RESEARCH- WHERE IS THE FOCUS?

    Nov 1, 2008, 00:00

  • PCN83 PERFORMANCE AND ADEQUACY OF PATIENT-PERSPECTIVE CRITERIA IN THE ASSESSMENT OF TEST-RETEST RELIABILITY- THE CASE OF THE PERFORM QUESTIONNAIRE

    Nov 1, 2008, 00:00

  • PIN15 COST-EFFECTIVENESS OF PALIVIZUMAB IN THE PROPHYLAXIS OF SEVERE BRONCHIOLITIS CAUSED BY RSV- RESULTS OF A DECISION MODEL WITH LOCAL DATA

    Nov 1, 2008, 00:00

  • PND14 MEDICATION COSTS OF PATIENTS WITH CYSTIC FIBROSIS (CF) IN GERMANY

    Nov 1, 2008, 00:00

  • PIN25 COST-EFFECTIVENESS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV) INCLUDING HERD PROTECTION IN TURKEY

    Nov 1, 2008, 00:00

  • PND6 GLATIRAMER ACETATE VERSUS INTERFERON BETA-1A FOR INTRAMUSCULAR ADMINISTRATION- A COMPARISON OF OUTCOMES AMONG MULTIPLE SCLEROSIS PATIENTS

    Nov 1, 2008, 00:00

  • PDB65 A COMPARISON OF DIABETES KNOWLEDGE AMONG RESIDENTS IN BANGKOK AND OTHER CENTRAL PROVINCES OF THAILAND

    Nov 1, 2008, 00:00

  • PCV42 COST-EFFECTIVENESS OF POPULATION-BASED STRATEGIES DIRECTED AT ALBUMINURIA

    Nov 1, 2008, 00:00

  • PMS47 USING HAQTO ESTIMATE HUI3 AND EQ-5D UTILITY VALUES IN SPANISH RHEUMATOID ARTHRITIS PATIENTS

    Nov 1, 2008, 00:00

  • MH7 PATIENT REPORTED OBJECTIVES AND PRIORITIES FOR THE TREATMENT OF SCHIZOPHRENIA IN GERMANY- A MIXED METHODS APPROACH TO CAPTURING THE PATIENTS PERSPECTIVE

    Nov 1, 2008, 00:00

  • PCV47 ECONOMIC EVALUATION OF AN ABDOMINAL AORTIC ANEURYSM SCREENING PROGRAM

    Nov 1, 2008, 00:00

  • PMS69 PATTERNS OF MORBIDITY AND DIRECT COSTS ASSOCIATED IN THE OSTEOPOROSIS SPANISH POPULATION SETTING

    Nov 1, 2008, 00:00

  • PSY34 COSTS AND PATIENT-REPORTED OUTCOMES (PRO) IN GERMAN PATIENTS WITH CHRONIC KNEE AND HIP PAIN

    Nov 1, 2008, 00:00

  • PCN29 ECONOMIC EVALUATION OF SUNITINIB FIRST-LINE FOR METASTATIC RENAL CELL CARCINOMAVERSUS SORAFENIB, TEMSIROLIMUS AND BEVACIZUMAB INTERFERON-ALFA IN THE SWEDISH HEALTH SERVICE SETTING

    Nov 1, 2008, 00:00

  • PCV82 CHANGE IN LIPID VALUES, TARGET LIPID VALUE ATTAINMENT, AND ANNUAL HEALTH CARE RESOURCE UTILIZATION AND COSTS AMONG PATIENTS INITIATING COMBINATION STATIN AND EXTENDED-RELEASE NIACIN THERAPY

    Nov 1, 2008, 00:00

  • PIN18 ANALYSIS OF COST-EFFECTIVENESS OF ITRACONAZOLE IN THE TREATMENT OF INVASIVE ASPERGILLOSIS IN TURKISH SETTING

    Nov 1, 2008, 00:00

  • PMS25 COST-EFFECTIVENESS OF RITUXIMAB (MABTHERA) COMPARED WITH TNF INHIBITORS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS (RA) IN POLAND

    Nov 1, 2008, 00:00

  • PCV3 COMPARISON OF GOAL ATTAINMENT RATES BETWEEN USERS OF SIMVASTATIN 40 MG AND OTHER STATINS

    Nov 1, 2008, 00:00

  • PSS8 A TOPIC DERMATITIS IN CHILDHOOD- WHAT 'DERMATOLOGICAL FUTURE' FOR THESE CHILDREN?

    Nov 1, 2008, 00:00

  • PG112 MODELING THE LONG-TERM COST-EFFECTIVENESS OF CRONIC HEP. B THERAPIES IN SPAIN

    Nov 1, 2008, 00:00

  • PDB6 EFFECTS OF PIOGLITAZONE AND ROSIGLITAZONE ON GLUCOSE AND THE CARDIOVASCULAR RISK FACTORS IN PATIENTS WITH TYPE 2 DIABETES- A META-ANALYSIS

    Nov 1, 2008, 00:00

  • PCV115 ASSESSING THE POTENTIAL BENEFITS OF CHANGING REIMBURSEMENT CRITERIA FOR LIPID LOWERINGTHERAPY IN KOREA

    Nov 1, 2008, 00:00

  • PHP39 LINKING HOSPITAL ADMISSION DATA INTO PRIMARY CARE RECORDS WITHIN THE GENERAL PRACTICE RESEARCH DATABASE

    Nov 1, 2008, 00:00

  • PCV85 STROKE PATIENT RESOURCE USE AND CAREGIVER BURDEN OUTCOMES BY SEVERITY (RECOVERY) STUDY- METHODS AND RESULTS FROM THE ATHENS STROKE REGISTRY

    Nov 1, 2008, 00:00

  • AR4 MEASUREMENT AND RATES OF ADHERENCE TO BIOLOGICS IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PCV19 THE TIME OF SUNRISE AND HOURS WITH DAYLIGHT MAY HAVE AN EFFECT ON THE SEASONALITY AND DIURNAL VARIATION OF A HEART ATTACK

    Nov 1, 2008, 00:00

  • PIH9 COST-EFFECTIVENESS OF LEVONORGESTREL-RELEASING INTRAUTERINE SYSTEM (LNG-IUS) FOR THE TREATMENT OF DYSFUNCTIONAL UTERINE BLEEDING (DUB) IN SPAIN

    Nov 1, 2008, 00:00

  • PDB37 IS INSULIN GLARGINE A COST-EFFECTIVE OPTION FOR TREATMENT OF PATIENTS NA AND AGE BELOW 65YEARS IN COMPARISON TO NPH AND PREMIX IN POLAND?

    Nov 1, 2008, 00:00

  • HT4 HEALTH TECHNOLOGY ASSESSMENTS- ARE THEY RELEVANT TO CLINICAL PRACTICE?

    Nov 1, 2008, 00:00

  • PDB67 PATIENT-CENTERED OUTCOMES IN THE ECONOMIC EVALUATION OF TYPE 2 DIABETES TREATMENT- A SYSTEMATIC REVIEW OF MODELING METHODS

    Nov 1, 2008, 00:00

  • PSS60 DERMATOLOGY LIFE QUALITY INDEX IS MORE SENSITIVE THAN PSORIASIS AREA AND SEVERITY INDEX TO MEASURE TREATMENT EFFECT IN PATIENTS WITH PSORIASIS- FINDINGS FROM THE PHOENIX I TRIAL

    Nov 1, 2008, 00:00

  • PIN41 DEVELOPING AN ECONOMIC MODEL OF GRAM COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI) FOR INPATIENT AND OUTPATIENT TREATMENT SETTINGS

    Nov 1, 2008, 00:00

  • PCV103 TECHNOLOGICAL INNOVATION AND THE DECISION-MAKING PROCESS IN ITALIAN HOSPITALS

    Nov 1, 2008, 00:00

  • PMS58 FIBROMYALGIA MOLDOFSKY QUESTIONNAIRE (FMQ)- USE OF A TOOL TO AID DIAGNOSIS

    Nov 1, 2008, 00:00

  • PIN10 THE ECONOMIC IMPACT OF LOWER HIV PREVALENCE ESTIMATES

    Nov 1, 2008, 00:00

  • PCASE3 USING IN-HOUSE STRATEGIES TO OVERCOME INCONSISTENCIES BETWEEN EXPENDITURES AND BUDGETING

    Nov 1, 2008, 00:00

  • PHC9 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN THE UK

    Nov 1, 2008, 00:00

  • PCN21 COST-EFFECTIVENESS OF LAPATINIB PLUS CAPECITABINE FORWOMEN WITH HER2 METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH TRATSTUZUMAB IN FINLAND

    Nov 1, 2008, 00:00

  • PMH35 COST ANALYSIS OF THE TRENDS IN HOSPITALISATION OF PATIENTS WITH SCHIZOPHRENIA IN SPAIN FROM 1980-2004

    Nov 1, 2008, 00:00

  • PCV70 COST-EFFECTIVENESS OF CLOPIDOGREL IN COMBINATION WITH ASPIRIN FOR ACUTE CORONARY SYNDROMES IN AUSTRALIA

    Nov 1, 2008, 00:00

  • PHC6 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN SPAIN

    Nov 1, 2008, 00:00

  • PMS68 ANTI-TUMOUR NECROSIS FACTOR- INHIBITOR DOSE CHANGES IN RHEUMATOID ARTHRITIS PATIENTS IN A PROSPECTIVE PATIENT REGISTRY SETTING

    Nov 1, 2008, 00:00

  • PMS9 PREVALENCE OF FIBROMYALGIA IN PORTUGAL

    Nov 1, 2008, 00:00

  • PG14 BUDGET IMPACT OF METHYLNALTREXONE SC ON A PUBLIC DRUG PROGRAM FORMULARY

    Nov 1, 2008, 00:00

  • PIN32 COSTS OF INTERMITTENT VERSUS CONTINUOUS ANTIRETROVIRAL THERAPY IN PATIENTS WITH CONTROLLED HIV INFECTION.A SUBSTUDY OF THE ANRS 106 WINDOW TRIAL

    Nov 1, 2008, 00:00

  • PIN11 COST-EFFECTIVENESS OF QUADRIVALENT HPV VACCINATION IN FINLAND

    Nov 1, 2008, 00:00

  • PMS41 COST-EFFECTIVENESS OF CELECOXIB COMPARED TO CONVENTIONAL NSAIDS AND NSAIDPPI COMBINATION THERAPY IN RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PIN45 IMPACT OF PATIENT-HEALTH CARE PROVIDER COMMUNICATION- THE HIV/AIDS PATIENTS PERSPECTIVES

    Nov 1, 2008, 00:00

  • PCV95 SOCIODEMOGRAPHIC AND CARDIOVASCULAR RISK FACTORS INFLUENCES ON EQ-5D SOCIAL PREFERENCES SCORES AND SELF-REPORTED HEALTH- A GENERAL POPULATION SURVEY IN ARGENTINA

    Nov 1, 2008, 00:00

  • PCN70 TREATMENT OF CHRONIC LYMPHOCYTIC LEUKAEMIA WITH THE RITUXIMAB, FLUDARABINE AND CYCLOPHOSPHAMIDE REGIMEN-AN ECONOMIC EVALUATION BASED ON OBSERVATIONAL DATA

    Nov 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154 (current)
  • 155
  • 156
  • 157
  • 158
  • 159
  • 160
  • »